Inclusion Criteria:

- Written informed consent obtained prior to any protocol-specific procedures

- Male and female patients with histologically confirmed melanoma

- At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG
PET/CT scan performed as part of routine clinical care

- Age >/= 18 years

- Life expectancy >/=3 months

- ECOG performance score of 0-2

Exclusion Criteria:

- Pregnant or breastfeeding females

- Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG
PET/CT scan until after the 18F MEL050 PET/CT scan

- Patients whose clinical care may be compromised because of the delay resulting from
performance of the 18F MEL050 PET/CT scan

- Patients whose only metastatic lesion is in the Central Nervous System

- Patients with urinary incontinence or patients who cannot comfortably hold their
urine for more than 90 minutes

- Any serious medical condition which the investigator feels may interfere with the
procedures or evaluations of the study

- Patients unwilling or unable to comply with protocol and patients with a history of
non compliance or inability to grant informed consent.